CURRICULUM VITAE
Alexandria T. Phan MD
Alexandria T. Phan MD
Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
M.D. F.A.C.P.
Department of Medicine
Division of Hematology and Oncology - Medicine
M.D. F.A.C.P.
HOME ADDRESS: |
Froedtert and MCW Clinical Cancer Center |
9200 W. Wisconsin Avenue |
Milwaukee, WI 53226 |
Phone: 414-805-4600 |
OFFICE ADDRESS: |
Froedtert Hospital |
9200 W Wisconsin Ave |
Milwaukee, WI 53226 |
Phone: 414-805-8292 |
Fax: 414-805-0618 |
Email: aphan@mcw.edu |
EDUCATION: |
07/1986 - 07/1990 Bachelor of Sciences, Biochemistry, University of California, Davis, CA |
07/1993 - 07/1997 Medicine Doctorate (Doctor of Medicine), University of California College of Medicine, Irvine, CA |
07/2014 - 07/2015 Certificate - Academic Medicine Leadership Development, University of Texas School of Public Health, Houston, TX |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
07/1997 - 07/1998 Intern, Internal Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030 |
07/1998 - 07/2000 Resident, Internal Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030 |
07/2000 - 07/2003 Fellowship, Hematology, Baylor College of Medicine and Affiliated Hospitals, Houston, TX 77030 |
07/2000 - 07/2003 Fellowship, Medical
Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 |
FACULTY APPOINTMENTS: |
07/2000 - 01/2013 Full-time Faculty Physician, University of Texas MD Anderson
Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 |
01/2013 - 01/2015 Full-time Faculty Physician, Houston Methodist Specialty Physician
Group, Smith Tower, 6550 Fannin, Suite 1101, Houston, TX 77030 |
01/2015 - 03/2016 Founder and Managing Partner, Full-time Consultant, Phan & Associates LLC, 3730 Kirby Drive, Suite 1200, Houston,, TX 77098 |
03/2015 - 03/2016 Full-time Faculty Physician, University of New Mexico Comprehensive Cancer Center, 1201 Camino de Salud, Albuquerque,, NM 87106 |
03/2016 - 08/2018 Full-Time Physician, CTCA – Southeastern Regional Medical Center, 600 Celebrate Life Parkway, Newnan, GA 30265 |
08/2018 - 01/2019 Founder and Managing Partner, Full-time Consultant, Phan & Associates LLC, 3730 Kirby Drive, Suite 1200, Houston,, TX 77098 |
01/2019 - 09/2021 Full-time Faculty Physician, University of Texas Health Science at
Tyler, 11937 U.S. Hwy. 271, Tyler, TX 75708 |
09/2021 - Present Founder and Managing Partner, Full-time Consultant, Phan & Associates LLC, 3730 Kirby Drive, Suite 1200, Houston, TX 77098 |
01/2023 - Present Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 |
HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS: |
07/2000 - 07/2003 Clinical Specialist, Internal Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 |
07/2003 - 01/2013 Faculty Attending Physician, GI Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 |
07/2006 - 07/2008 Faculty Attending Physician, General Medical Oncology Consultation Services, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 |
01/2012 - 01/2014 Clinical Specialist, Internal Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 |
01/2013 - 01/2018 Faculty Attending Physician, Internal medicine, Hematology-Oncology, Houston Methodist Hospital – Texas Medical Center Cancer Center, Smith Tower, 6550 Fannin, Suite 1101, Houston, TX 77030 |
03/2015 - 03/2016 Faculty Attending Physician, Medical Oncology – Hematology, University of New Mexico Comprehensive Cancer Center, 1201 Camino de Salud, Albuquerque, NM 87106 |
03/2016 - 08/2018 Attending Physician, GI Medical Oncology Section, CTCA – Southeastern Regional Medical Center, 600 Celebrate Life Pkwy, Newnan, GA 30265 |
08/2018 - 01/2019 Consultant Physician, GI Medical Oncology Private Practice, Phan & Associates LLC, 3730 Kirby Drive, Ste 1200, Houston, TX 77098 |
01/2019 - 09/2021 Faculty Attending Physician / Cancer
Center Director, Internal Medicine, Hematology-Oncology, University of Texas Health Science Center, 11937 US Hwy 271, Tyler, TX 75708 |
09/2021 - Present Consultant Physician, GI Medical Oncology Private Practice, Phan & Associates LLC, 3730 Kirby Dr., Ste 1200, Houston, TX 77098 |
01/2023 - Present Attending Physican, Froedtert Memorial Lutheran Hospital, 9200 W Wisconsin Ave, Milwaukee, WI 53226 |
RESEARCH ADMINISTRATIVE APPOINTMENTS: |
07/2003 - 07/2009 Assistant Professor, GI Medical Oncology Department, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 |
07/2009 - 01/2013 Associate Professor, GI Medical Oncology Department, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 |
09/2010 - 01/2013 Associate Professor (Adjunct), University of Texas Graduate School of Biomedical Sciences, 6767 Bertner Avenue, Ste S38344, Houston, TX 77030 |
01/2013 - 01/2015 Associate Professor, Internal Medicine, Hematology-Oncology, Houston Methodist Institute of Academic Medicine, Smith Tower, 6550 Fannin, Suite 1101, Houston, TX 77030 |
01/2015 - 03/2015 Professor, Internal Medicine, Hematology-Oncology, Houston Methodist Institute of Academic Medicine, Smith Tower, 6550 Fannin, Suite 1101, Houston, TX 77030 |
03/2015 - 03/2016 Professor, University of New Mexico Comprehensive Cancer Center, 1201 Camino de Salud, Albuquerque, NM 87106 |
03/2017 - 01/2019 Professor (Adjunct), Morehouse School of Medicine, 720 Westview Drive, SW, Atlanta, GA 30310 |
01/2019 - 09/2021 Professor, Internal Medicine, Hematology-Oncology, University of Texas Health Science Center at Tyler, 11937 US Hwy 271, Tyler, TX 75708 |
09/2019 - 09/2021 Professor (2nd appointment), Epidemiology and Biostatistics, School of Community & Rural Health, University of Texas Health Science Center at Tyler, 11937 US Hwy 271, Tyler, TX 75708 |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
Internal Medicine
American Board of Internal Medicine | 01/2001 | 01/2031 |
Medical Oncology
American Board of Internal Medicine | 01/2003 | 01/2033 |
Hematology
American Board of Hematology | 01/2005 | 01/2015 |
Certificates | Issued By | Issue Date | Expiration |
DEA | Wisconsin | None | |
Licensure | Number | Issue Date | Expiration |
Texas | L3069 | 12/07/2001 | 08/31/2023 |
New Mexico | MD2016-0653 | 08/25/2016 | 07/01/2017 |
Georgia | 077891 | 05/04/2017 | 06/30/2020 |
AWARDS AND HONORS: |
1999 - 2000 Teaching Excellence as House Officer, Baylor College of Medicine (Houston, Texas) |
2001 - 2002 C.D. Howe Award for Clinical Excellence in Medical Oncology, University of Texas M D Anderson Cancer Center (Houston, Texas) |
2006 - 2007 Teacher of the Year Award Division of Cancer Medicine, University of Texas M D Anderson Cancer Center (Houston, Texas) |
2006 - 2007 Gerald P. Bodey Award for Excellence in Education Division of Cancer Medicine, University of Texas MD Anderson Cancer Center (Houston, Texas) |
2007 - 2008 Teacher of the Year Award Division of Cancer Medicine, University of Texas M D Anderson Cancer Center (Houston, Texas) |
2008 - 2009 Teacher of the Year Award Division of Cancer Medicine, University of Texas M D Anderson Cancer Center (Houston, Texas) |
2008 - 2009 Leadership in Excellence Award Division of Cancer Medicine, University of Texas M D Anderson Cancer Center (Houston, Texas) |
2008 - 2009 Gerald P. Bodey Award for Excellence in Education Division of Cancer Medicine, University of Texas M D Anderson Cancer Center (Houston, Texas) |
2009 - 2010 Gerald P. Bodey Award for Excellence in Education Division of Cancer Medicine, University of Texas M D Anderson Cancer Center (Houston, Texas) |
2010 - 2011 Cancer Center Faculty Educator of the Year, University of Texas M D Anderson Cancer Center (Houston, Texas) |
2014 - 2015 Graduate Medical Education Teacher of the Year, Houston Methodist Hospitals System (Houston, Texas) |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
1990 - Present American Medical Association (AMA) (Member) |
2000 - Present American Society of Clinical Oncology
(ASCO) (Member) |
2003 - Present National Cancer Institute (NCI) (Member) |
2003 - Present Harris County Medical Society (Member) |
2003 - Present Texas Medical Association (TMA) (Member) |
2007 - Present North American Neuroendocrine Tumor
Society (NANETS) (Member) |
2008 Multinational Association of Supportive
Care in Cancer (MASCC) (Member, Scientific Program Committee) |
2009 - 2012 American Society of Clinical Oncology
(ASCO) (Member, Non-Colorectal Scientific Planning) |
2009 - 2018 SouthWestern Oncology Group (SWOG) (Member) |
2010 - Present American College of Physicians (ACP) (Member) |
2010 - 2013 American Society of Clinical Oncology
(ASCO) (Committee Member, Life-Long Learning Subcommittee) |
2010 - 2018 National Cancer Institute (NCI) (Member, NCI Neuroendocrine Advisory Task Force) |
2011 - Present American Society of Hematology (ASH) (Member) |
2013 - Present European Neuroendocrine Tumor Society
(ENETS) (Member) |
2013 - 2016 SouthWestern Oncology Group (SWOG) (Member, GI Cancers Steering Committee) |
2015 - Present European Society of Clinical Oncology
(ESMO) (Member) |
2015 - 2019 American Joint Committee of Cancer
(AJCC) (Co-Chair, Adrenocortical Carcinoma AJCC Staging
Version 8 Subcommittee) |
2015 - Present American College of Physicians (ACP) (Fellow of American College of Physicians) |
2015 - Present American Association of Clinical
Research (AACR) (Member) |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Editorial Board |
2009 - Present Journal of GI Oncology |
2013 - Present Advances in Clinical Oncology |
Journal Review |
2006 - 2007 International Journal of Radiation Oncology, Biology, Physics |
2007 International Journal of Gastrointestinal Malignancy |
2008 Annals of Oncology |
2009 - 2018 Cancer |
2009 - 2018 Neuroendocrinology |
2009 - 2018 Journal of Surgical Oncology |
2013 - Present Advances in Clinical Oncology |
2016 - Present Drugs |
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
2007 - 2017 Key Opinion Leader and Advisory Committee(s) Member, Neuroendocrine Tumor, Novartis USA and Global |
2013 - 2019 Key Opinion Leader and Advisory Committee(s) Member, Colorectal Cancer, Genentech USA |
2013 - 2018 Key Opinion Leader and Advisory Committee(s) Member, Gastroesophageal Cancer, Eli Lilly USA |
2013 - 2017 Key Opinion Leader and Advisory Committee(s) Member, Pancreatic Cancer, Celgene USA |
2013 - 2015 Key Opinion Leader and Advisory Committee(s) Member, Hepatocellular Cancer, Bayer USA |
2014 - Present Key Opinion Leader and Advisory Committee(s) Member, Neuroendocrine Tumor, Ipsen USA and Global |
2014 - 2019 Key Opinion Leader and Advisory Committee(s) Member, Neuroendocrine Tumor, Lexicon USA |
2019 - Present Key Opinion Leader and Advisory Committee(s) Member, Digital Healthcare, Roche Diagnostic USA |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
Local |
“Management of Adrenal Cancers”, Division Grand Round, Surgical Oncology Division, University of Texas M D Anderson Cancer Center Houston Texas, 2004 |
“Advances Management of Upper GI Cancers”, Division Grand Round, Surgical Oncology Division, University of Texas M D Anderson Cancer Center, Houston Texas, 2006 |
“Management of Advanced Gastric Cancer”, Division Grand Round, Surgical Oncology Division, University of Texas M D Anderson Cancer Center, Houston Texas, 2007 |
“Challenging Cases in GI Malignant Diseases-Diagnostic and Therapeutic”, Medical Oncology & Hematology Fellowship Lectureship, Baylor College of Medicine, Houston, Texas, 2007 |
“Carcinoid Tumors”, John Peter Smith Hospital Grand Rounds, Texas Medical Association’s Physician Oncology Education Program, Ft Worth, TX, 2008 |
Invited Board Review Faculty, “Neuroendocrine Tumors”, Comprehensive Hematology and Medical Oncology Board Review, Baylor College of Medicine and UT M D Anderson Cancer Center
Houston, Texas, 2010 |
“Resectable Gastroesophageal Cancers”, Lectureship Series via TMA’s Physician Oncology Education Program, The Center for Cancer and Blood Disorders
Fort Worth, Texas, 2010 |
Invited Board Review Faculty, “Neuroendocrine Tumors”, Comprehensive Hematology and Medical Oncology Board Review, Baylor College of Medicine and UT M D Anderson Cancer Center
Houston, Texas, 2011 |
“Management of NET & Adrenal Cancers”, MD Anderson Cancer Center Institution Grand Round, University of Texas M D Anderson Cancer Center, Houston Texas, 2012 |
Invited Board Review Faculty, “Neuroendocrine Tumors”, Comprehensive Hematology and Medical Oncology Board Review, Baylor College of Medicine and UT M D Anderson Cancer Center
Houston, Texas, 2012 |
“Therapeutic Development of Rare Cancers”, Houston Methodist Research Institute Symposium, Houston Methodist, Houston, Texas, 2012 |
“Multidisciplinary Team Management of GI Malignancies”, Institutional Oncology Grand Rounds, Methodist Hospital in San Jacinto, Texas, 2013 |
Course Director and Chair, “Multidisciplinary Management of Neuroendocrine Tumor”, Carcinoid Foundation Regional Patients Neuroendocrine, Houston, Texas, 2013 |
“The NET Lessons”, Institutional Oncology Grand Rounds, Houston Methodist in Houston, Texas, 2013 |
“Oncologic Emergencies, Part 1”, Medicine Grand Rounds, Houston Methodist in Houston, Texas, 2014 |
“Multidisciplinary Management of Esophageal Cancers”, Combined Institutional Surgery and Oncology Grand Rounds, Houston Methodist in Houston, Texas, 2014 |
“Neuroendocrine Tumor – Lessons Learn and What’s New in Horizon”, Grand Round, University of Texas Health Science Center at Tyler
Tyler, Texas, 2019 |
“Pancreatic Cancer – An update for Primary Care Providers”, Grand Round, University of Texas Health Science Center at Tyler
Tyler, Texas, 2020 |
Regional |
“Advances in Adrenal Cancers”, Division of Endocrinology Grand Rounds, University of Michigan – Division of Endocrinology, Ann Arbor, Michigan, 2008 |
“Advances in Medical Management of Adrenocortical Carcinoma”, Combined Surgery and Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee, Wisconsin, 2009 |
“Multidisciplinary Approach to GI Malignancies”, Medical Oncology & Hematology Fellowship Visiting Professorship, University of Cincinnati Cancer Institute, Cincinnati, Ohio, 2009 |
“Multidisciplinary Management of Gastroesophageal Cancers”, Division of Medicine Grand Rounds, University of Cincinnati, Cincinnati, Ohio, 2009 |
“Orphan Disease – Rational Approach to Drug Development”, Combined Oncology and Medicine Grand Rounds, Medical University of South Carolina, Charleston, South Carolina, 2010 |
Oral Poster Presenter, Non-Colorectal Scientific Symposium, Abstract 4001: A prospective, multi-institutional phase II study of GW786034 (pazopanib)
and depot octreotide (Sandostatin LAR) in advanced low-grade neuroendocrine carcinoma
(LGNEC)
Scientific Symposium: Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and
Quality of Life, American Society of Clinical Oncology Annual Meeting
Chicago, Illinois, 2010 |
Co-Chair, Non-Colorectal Scientific Oral Poster Presentations Session American Society of Clinical, Oncology Annual Meeting, Chicago, Illinois, 2010 |
Oral Poster Presenter
Non-Colorectal Posters Discussion Session, Abstract 233 – Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine
tumors (pNETs): A subgroup analysis from the CLARINET study, Gastrointestinal Symposium American Society of Clinical Oncology, San Francisco, California, 2011 |
Oral Presenter, Multidisciplinary Management of Gastroesophageal Cancers Track, “Strategies for Induction Therapy in Esophageal-Gastric Cancer: How should we place
chemotherapy, radiation and targeted agents?”, Gastrointestinal Symposium American Society of Clinical Oncology, San Francisco, California, 2011 |
“Management of Adrenal Cancers”, Institutional Grand Rounds, Medical College of Wisconsin
Milwaukee, Wisconsin, 2011 |
“Therapeutic Development of Rare Cancers”, Hollings Cancer Center Grand Rounds Medical, University of South Carolina (MUSC)
Charleston, South Carolina, 2012 |
“Advances in Adrenal Cancers”, Division of Endocrinology Grand Rounds, University of Colorado – Division of Endocrinology
Denver, Colorado, 2014 |
“Past, Present, and Future of Neuroendocrine Tumors”, Institutional Oncology Grand Rounds, Cedars Sinai Samuel Oschin Comprehensive Cancer Center
Los Angeles, California, 2015 |
Invited Faculty, “Ramicurimab in Advanced Gastroesophageal Cancers”, Lilly Sponsored Lunch Scientific Symposium
Annual Great Debates in GI Malignancies, New York, New York, 2015 |
“Past, Present and Future Management of Advanced Neuroendocrine Tumors”, Cancer Center Grand Rounds, University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, 2016 |
"Multidisciplinary Management of Pancreatic NET", Pancreatic Cancer Clinical Symposium, Piedmont Cancer Center and Medical College of Wisconsin, Atlanta, Georgia, 2018 |
National |
“Optimizing treatment options for Pancreatic NET”, Invited Speaker, Global Ipsen Lunch Symposium, Asian Pacific Neuroendocrine Tumors (APNETS) Congress
Penang, Malaysia, 2015 |
“Past, Present and Future Management of Advanced Neuroendocrine Tumors”, Lectureship Series, British Columbia Cancer Agency
Victoria Island, British Columbia, Canada, 2016 |
“Clinical Updates in Management of NETs”, Visiting Professorship, McGill University Cancer Center, Montreal, Quebec. Cananda, 2016 |
“Advances in the Management of Gastrointestinal and Pancreatic NETS”, Visiting Professorship, Combined Endocrine and Cancer Grand Rounds, Goodman Cancer Research Center
McGill University Hospital Center
Montreal, Quebec, Canada, 2016 |
“Optimal Management of GI and Pancreatic NETS”, Visiting Professorship, Special Scientific Dinner Symposium, Sponsored by Sunnybrook Health Sciences, Toronto, Ontario, Canada, 2016 |
“Practical considerations in management of gastroenteropancreatic NETS”, Lectureship Series, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada, 2016 |
“Update on NETs therapeutic, scientific data from ASCO GI, ESMO”, Hospital Grand Rounds, Hôpital Saint-Luc\, Montréal, Quebec, Canada, 2016 |
“Advances in the Management of Gastrointestinal and Pancreatic NETS”, Lectureship Series, Jewish Hospital Cancer Center, Montreal, Quebec, Canada, 2016 |
“Past, Present and Future Management of Advanced Neuroendocrine Tumors”, Lectureship Series, British Columbia Cancer Agency Vancouver, British Columbia, Canada, 2016 |
“Insights from Clarinet trial and your clinical experience with Somatuline”, Lectureship Series, Princess Margaret Cancer Center, Toronto, Ontario, Canada, 2016 |
"Management of Challenging Cases in Gastrointestinal and Pancreatic NETS”, Invited Professorship, Combined JHC and MUHC Scientific Symposium
Montreal, Quebec, Canada, 2016 |
“Translating Results of CLARINET into Clinical Practice”, Lectureship Series, Burnaby Hospital Cancer Clinic, Burnaby, British Columbia, Canada, 2016 |
“Practical Considerations in the Management of Neuroendocrine Tumors”, Grand Round / Visiting Professorship, Toronto General Hospital, Toronto, Ontario, Canada, 2017 |
“Practical Considerations in the Management of Neuroendocrine Tumors”, Visiting Professorship, Niagara Health System, Toronto, Ontario, Canada, 2017 |
“Practical Considerations in the Management of Neuroendocrine Tumors”, Grand Round / Visiting Professorship, Princess Margaret Hospital, Toronto, Ontario, Canada, 2017 |
Keynote Speaker, “Practical Considerations in the Management of Neuroendocrine Tumors”, 42nd Annual Congress of AMHOQ, Montreal, Quebec, Canada, 2017 |
International |
“Gastroesophageal Cancers”, Visiting Professorship Lecture Series, MD Anderson Cancer Center International Physicians Relations
Albert Einstein Hospital
Sao Paulo, Brazil, 2010 |
“Neuroendocrine Tumors”, Visiting Professorship Lecture Series, MD Anderson Cancer Center International Physicians Relations
Albert Einstein Hospital
Sao Paulo, Brazil, 2010 |
“CLARINET Trial Results & Management of Neuroendocrine Tumors”, Visiting Professorship / Institutional Oncology Grand Rounds, Asan Medical Center, Seoul, Korea, 2015 |
“The management of Advanced NETs: Current and Future Directions”, Cancer Institute Grand Round / Visiting Professorship, Singapore National Cancer Center, Singapore, 2015 |
“Management of advanced NETs”, Visiting Professorship, National Taiwan University Hospital Cancer Research Institute, Taipei, Taiwan, 2015 |
“Future direction for targeted therapy in well differentiated NET”, Visiting Professorship, Hong Kong National Cancer Institute, Hong Kong, 2015 |
Plenary Session Keynote Speaker, “Future Direction for Targeted Therapy In Well-Differentiated NET”, sian Pacific
Neuroendocrine Tumors (APNETS) Congress, Penang, Malaysia, 2015 |
“CLARINET Trial Results & Management of Neuroendocrine Tumors”, Visiting Professorship, Korea Oncology Society, Seoul, Korea, 2015 |
“NET management with a focus on pancreatic and midgut NET”, Visiting Professorship, National Cancer Institute, Kuala Lumpur, Malaysia, 2015 |
“Optimizing treatment options for Pancreatic NET”, Invited Speaker, Global Ipsen Lunch Symposium, Brazilian Congress of Clinical Oncology
Rio de Janeiro, Brazil, 2017 |
EXTRAMURAL TEACHING: |
Medical Student Education |
2005 - 2012 University of Texas M D Anderson Cancer Center, Houston, Texas, “Carcinoid and Carcinoid Syndrome”
Novartis Sponsored Educational Lecture Series |
2007 University of Texas M D Anderson Cancer Center, Houston, Texas, “Anemia Work up and Management” Physician Assistant Educational Core Series |
2007 - 2012 University of Texas M D Anderson Cancer Center Houston, Texas, “Gastroesophageal Cancers”
Physician Assistant Educational Core Series |
2007 - 2012 University of Texas M D Anderson Cancer Center, Houston, Texas, “Neuroendocrine Tumors”
Physician Assistant Educational Core Series |
2007 University of Texas M D Anderson Cancer Center, Houston, Texas, Best of ASCO 2007 in Gastroesophageal Cancer” Physician Assistant Educational Core Series |
2008 - 2012 University of Texas M D Anderson Cancer Center, Houston, Texas, “Perioperative Therapy for Upper GI Cancers” Surgical Fellows Core Lecture Series |
2013 Houston Methodist Hospitals System Fellows Core Lecture Series, “Introduction to Hematology and Medical Oncology For Trainees” |
2014 - 2016 Houston Methodist Hospitals System Fellows Core Lecture Series, “Fundamentals of Hepatobiliary and Pancreatic Cancers” |
2014 - 2016 Houston Methodist Hospitals System Fellows Core Lecture Series, “Fundamentals of Gastroesophageal Cancers” |
2014 - 2016 Houston Methodist Hospitals System Fellows Core Lecture Series, “Current Evidence Based Management of Neuroendocrine Tumors” |
2014 - 2016 Houston Methodist Hospitals System Fellows Core Lecture Series, “Fundamentals of Colorectal and Anal Cancers” |
2014 - 2016 Houston Methodist Hospitals System Fellows Core Lecture Series, “Basics of Sarcomatoid Malignancy” |
2014 - 2016 Houston Methodist Hospitals System Fellows Core Lecture Series, “Introduction to the Basics of Cancer Clinical Research” |
Resident and Fellow Education |
2004 - 2012 University of Texas at Houston School of Medicine, Houston, Texas, “Oncologic Emergencies”
Internal Medicine Residency Program - Core Medical Oncology Didactics |
2004 - 2012 University of Texas M D Anderson Cancer Center Houston, Texas, “Gastroesophageal Cancers”
Hematology-Oncology Fellows Core Lecture Series |
2004 - 2012 University of Texas M D Anderson Cancer Center Houston, Texas, “Neuroendocrine Tumors”
Hematology-Oncology Fellows Core Lecture Series |
2004 - 2012 University of Texas at Houston School of Medicine, Houston, Texas, “Gastroesophageal Cancers”
Internal Medicine Residency Program - Core Medical Oncology Didactics |
2007 Baylor College of Medicine, Houston, Texas, “Challenging Cases in GI Malignant Diseases-Diagnostic and Therapeutic” Hematology-Oncology Fellows Lecture Series |
2008 - 2012 University of Texas M D Anderson Cancer Center Houston, Texas, “Adrenal Cortical Carcinoma”
Hematology-Oncology Fellows Core Lecture Series |
2014 - 2016 Dr. Asmita Patel, Houston Methodist Hospital Hem-Onc Fellowship, Clinical teaching and formal teaching in continuity clinic and inpatient services |
2014 - 2016 Dr. Sravanti Teegavarapu, Houston Methodist Hospital Hem-Onc Fellowship, Clinical teaching and formal teaching in continuity clinic and inpatient services |
2015 - 2016 Dr. X. Rain Nan, Houston Methodist Hospital Internal Medicine Residency, Clinical teaching and formal teaching in continuity clinic and inpatient services |
2015 - 2016 Dr. Yan Xing, Houston Methodist Hospital Hem-Onc Fellowship, Clinical teaching and formal teaching in continuity clinic and inpatient services |
2015 - 2016 Dr. Akash Mukherjee, Houston Methodist Hospital Hem-Onc Fellowship, Clinical teaching and formal teaching in continuity clinic and inpatient services |
EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Faculty |
Dr. Stefan Mao, University of Texas M D Anderson Cancer Center Houston, Texas, 2006 Hematology-Med Oncology Fellowship Program, Mentoring in continuity clinic and formal teaching |
Dr. Ajay Nooka, Internal Medicine Residency Program University of Arkansas Fayetteville, Arkansas, 2006 Mentoring in continuity clinic and formal teaching |
Dr. Wen Zhang, Medical Oncology at Cancer Hospital at Fudan University, Fudan, China, 2007 Mentoring in career development and clinical research |
Dr. Nuruddin Jooma, Baylor College of Medicine Houston, Texas, 2007 - 2008 Mentoring in continuity clinic and formal teaching, Hematology-Med Oncology Fellowship |
Dr. Ignacio Juez Martel, Medical Oncology at MD Anderson Cancer Center in Spain Madrid, Spain, 2007 Mentoring in career development and clinical research |
Dr. Garth Beinart, University of Texas M D Anderson Cancer Center Houston, Texas, 2007 Mentoring in continuity clinic and formal teaching, Med Oncology Fellowship |
Dr. Kareem Abdelhadi, University of Texas Medical Branch. Galveston, Texas, 2007 Mentoring in continuity clinic and formal teaching, Internal Medicine Residency Program |
Dr. Fadi Braiteh, University of Texas M D Anderson Cancer Center Houston, Texas, 2008 - 2009 Mentoring in continuity clinic, formal teaching, along with career development, Hematology-Med Oncology Fellowship |
Dr. Heather Brooks, University of Texas M D Anderson Cancer Center Houston, Texas, 2008 - 2010 Mentoring in continuity clinic, formal teaching, along with career development, Hematology-Med Oncology Fellowship |
Dr. Putao Cen, University of Texas M D Anderson Cancer Center, Houston, Texas, 2008 Mentoring in continuity clinic, formal teaching, along with career development, Hematology-Med Oncology Fellowship |
Dr. Elisabet Manasanch, University of Massachusetts Worcester, Massachusetts, 2008 Mentoring in continuity clinic, along with career development and clinical research, Internal Medicine Residency Program |
Dr. Nishin Bhakhamkar, University of Texas M D Anderson Cancer Center Houston, Texas, 2009 - 2012 Mentoring in continuity clinic, formal teaching, along with career development, Hematology-Med Oncology Fellowship |
Dr. Jane Huang, University of Texas M D Anderson Cancer Center Houston, Texas, 2009 - 2012 Mentoring in continuity clinic, formal teaching, along with career development, Hematology-Med Oncology Fellowship |
Dr. Rachna Shroff, University of Texas M D Anderson Cancer Center Houston, Texas, 2009 - 2012 Mentoring in continuity clinic, formal teaching, along with career development, Hematology-Med Oncology Fellowship |
Dr. Paola Jimenez, Colombia National Cancer Institute Bogota, Colombia, 2010 Mentoring in continuity clinic, formal teaching, along with career development, Hematology-Medical Oncology Fellowship |
Dr. Alexandra Zarzour, University of Texas M D Anderson Cancer Center Houston, Texas, 2010 - 2011 Mentoring in continuity clinic, formal teaching, along with career development, Hematology-Med Oncology Fellowship |
Dr. Sravanti Teegavarapu, Houston Methodist Hospital, 2014 - 2016 Hem-Onc Fellowship Career Mentor, Development of GI medical oncology clinical academic career Project Mentor, Overcome resistance of mTOR inhibitors with autophagy in carcinoid tumors |
Dr. X. Rain Nan, Houston Methodist Hospital Internal Medicine Residency Career Mentor, 2014 - 2016 Becoming a hematology-oncology fellow
Project Mentor, Molecular risk stratifications of early rectal adenocarcinoma Project Mentor, Clinical outcomes and indications in patients receiving
leukopharesis |
Dr. Bidhan Das, Division of Surgery, Department of Colorectal Surgery at the University of Texas Health Science at Houston
Professional Coaching and Development, 2014 - Present Academic Medicine
Career Mentor, Professional Coaching and Development, Academic Medicine
Career Mentor |
Dr. George Chen, Section of BMT, Division of Hematology-Oncology, Department of Internal Medicine at Roswell Comprehensive Cancer Center in Buffalo, NY, 2014 - Present Professional Coaching and Development, Academic Medicine
Career Mentor, Academic Medicine |
ADMINISTRATIVE / PROGAMMATIC / LEADERSHIP DESCRIPTION OF RESPONSIBILITIES AND ACTIVITIES : |
07/2000 - 01/2013 University of Texas M D Anderson Cancer Center
Total Efforts Percentage Administrative/Programmatic/Leadership 2%
Two percent of my time was for administrative responsibilities and committees at M D Anderson Cancer Center. Selected committees involved are listed below:
● Chairman, Gastric Cancer Multidisciplinary Conference (2010-2012)
● Chairman, Neuroendocrine Tumor Multidisciplinary Conference (2009-2013)
● Member, Annual Exemplary Employee Selection Committee (2004-2006)
● Member, Clinical Research Committee (2007-2012)
● Member, Colorectal Section, Cancer Survivorship Course (2010-2012)
● Member, Credentials Committee of the Medical Staff (2007-2010)
● Member, Executive Hem-Oncology Fellowship Program Steering Committee (2005- 2010)
● Member, Faculty Career Navigators Panel (2007-2010)
● Member, Hematology-Oncology Fellowship Program Committee (2009- 2012)
● Member, Institutional Research Grant Review Committee (2009-2012)
● Member, Outpatient Neutropenic Pathway Committee (2005-2007)
● Associate Fellowship Director GI Cancer Session Annual Hematology- Oncology Board Review Course, Chairman (2009-2013)
● Planning Exec Member, Annual Hem and Medical Oncology Board Review Course, (2007-2013)
● Program Director, GI Medical Oncology Education/Clinical Rotation (2005- 2010)
|
01/2013 - 01/2015 Houston Methodist Cancer Center
Total Efforts Percentage Administrative/Programmatic/Leadership 5%
Five percent of my time was for administrative responsibilities and committees at M D Anderson Cancer Center. Selected committees involved are listed below:
● Chairman, Gastric Cancer Multidisciplinary Conference (2010-2012)
● Chairman, Neuroendocrine Tumor Multidisciplinary Conference (2009-2013)
● Member, Annual Exemplary Employee Selection Committee (2004-2006)
● Member, Clinical Research Committee (2007-2012)
● Member, Colorectal Section, Cancer Survivorship Course (2010-2012)
● Member, Credentials Committee of the Medical Staff (2007-2010)
● Member, Executive Hem-Oncology Fellowship Program Steering Committee (2005- 2010)
● Member, Faculty Career Navigators Panel (2007-2010)
● Member, Hematology-Oncology Fellowship Program Committee (2009-2012)
● Member, Institutional Research Grant Review Committee (2009-2012)
● Member, Outpatient Neutropenic Pathway Committee (2005-2007)
● Associate Fellowship Director GI Cancer Session Annual Hematology-Oncology Board Review Course, Chairman (2009-2013)
● Planning Exec Member, Annual Hem and Medical Oncology Board Review Course, (2007-2013)
● Program Director, GI Medical Oncology Education/Clinical Rotation (2005- 2010)
|
03/2017 - 08/2018 CTCA Southeastern Regional Medical Center
Total Efforts Percentage Administrative/Programmatic/Leadership 15%
I was the National Director for the enterprise GI Cancer Institute, responsible for overseeing the quality, and strategies of GI Cancer Service Line of 5 hospitals in 5 different states (Arizona, Georgia, Illinois, Oklahoma, and Pennsylvania). My responsibilities entailed establishing best practice clinical pathways, recommending appropriate drug formularies, and developing strategic programs for clinical research and clinical distinctiveness to the Southeastern Regional Medical Center and to the CTCA enterprise. Over the course of less than 12 months, I was involved in market analysis, business planning, working cross-function and cross-discipline to develop the infrastructure and establish Theranostic Treatment Center and Neuroendocrine Tumor Center of Excellence – only one in Georgia. We were the first to treat patients with metastatic well-differentiated neuroendocrine tumor on protocol and commercially with peptide radiolabel radiotherapy (PRRT). |
CLINICAL CARE DESCRIPTION OF RESPONSIBILITIES AND ACTIVITIES: |
07/2000 - 01/2013 University of Texas M D Anderson Cancer Center
Total Efforts Percentage Clinical Care 60%
Sixty percent of my time was devoted to clinical practice. I spent 2.5 days per week of dedicated time to
outpatient clinics, and about 10-12 weeks per year for inpatient general oncology service. My clinic average was 25-35 per full day in clinic, with support by midlevel provider along with clinic nurse and scheduler/medical assistant. My area of focus was upper GI malignancies, adrenal malignancies, and neuroendocrine tumors but I was able to provide care for all patients with GI malignancies. Inpatient responsibility accounts for seeing patients on GI Medical Oncology inpatient service and providing inpatient consultation.
|
01/2013 - 01/2015 Houston Methodist Cancer Center
Total Efforts Percentage Clinical Care 70%
Houston Methodist (HM) Cancer Center was primarily function as a private practice model without any disease- specific oncology, except for breast medical oncology. My clinical practice was the first GI medical oncology practice in the hospital system, developed without any previous Houston Methodist referral patterns, competing against large established general oncology practices. Two and one-half days per week were dedicated for seeing patients with GI and rare malignancies. The clinical practice was supported only by shared medical assistant. I was seeing 15-20 follow up patients, and 3-6 new patients and consultations per day, in outpatient clinic. 0.5 day per week dedicated for GI High Genetic Risk clinic, co-managing with the genetic counselor and caring for patients with high risk and/or confirmed hereditary syndrome at risk for GI/endocrine malignancies. In addition to having the inpatient responsibility of staffing a General Oncology inpatient service for 12- 15 weeks per year, I was also responsible for doing inpatient consultation 24/7, for all of my patients who got admitted and new consultations directed to me. My clinical time is focused on developing specialty GI medical oncology clinical practice, while formulating and cultivating focused multidisciplinary teams optimal in caring for patients with various gastrointestinal / endocrine malignancies. Therefore, I have 3 days per week of dedicated time to outpatient clinics, 12-15 weeks of inpatient general oncology service, while always being responsible for all inpatient specialty consultations relating to GI/endocrine malignancies.
|
03/2017 - 08/2018 CTCA Southeastern Regional Medical Center
Total Efforts Percentage Clinical Care 70%
I had 4 days of clinic, seeing 17-22 patients per day without midlevel support. My area of focus continued to be in GI malignancies and neuroendocrine/endocrine malignancies. I also chaired the GI tumor board both onsite as well as for the enterprise-wise for 5 hospitals of the CTCA system. Because my area of neuroendocrine tumor, I was seeing patients that came from other states and countries to see me, and many of my patients had followed me to have continuity of care. I saw all GI malignancies and most endocrine malignancies, and care for each patient was individualized and personalized while practicing multidisciplinary management. |
EDUCATION DESCRIPTIONS OF RESPONSIBILITIES AND ACTIVITIES: |
07/2000 - 01/2013 University of Texas M D Anderson Cancer Center
Total Efforts Percentage Education 18%
During my tenure at M D Anderson, I was always participated in clinical and didactic formal teaching for trainees. I was very privileged to mentor many local, national and international trainees at all levels and disciplines. I served as Education Program Director for GI Medical Oncology Department, Member of the M D Anderson Cancer Hematology Oncology Fellowship Program Executive Steering Committee, and Associate Program Director for M D Anderson Hematology Oncology Fellowship Program. As the Program Director of GI Medical Oncology program and Associate Program Director of the Hematology- Oncology Fellowship at the University of Texas M D Anderson Cancer Center, I directed the clinical teaching for the fellows, rotating fellows, residents, interns, medical students from the Houston-area medical schools, other national and international academic institutions. Due to my expertise in neuroendocrine tumor and GI malignancies, I had oversight of the teaching and mentoring of national and international fellowships/observerships I have given Grand Rounds, Lectureships and Visiting Professorships both within M D Anderson and other national and international academic institutions. In these positions, I developed educational curriculum, performed evaluations, and working 1:1 for remedial training of fellows in jeopardy of training incompletion. My efforts and passions for education had earned many awards and recognitions (including Division of Medicine Best Teacher, Institutional Best Educator, nominee for Gerald P Bodey Excellence in Education, and Division of Medicine Excellence in Leadership). |
01/2013 - 01/2015 Houston Methodist Cancer Center
Total Efforts Percentage Education 15%
When I came to Houston Methodist (HM), there was no Hematology-Oncology Fellowship Program. I founded, developed, wrote and applied for an ACGME accredited combined fellowship program, without any administrative or programmatic support. We received ACGME approval in February 2014, and the first HM fellow started in July 2014. The program consisted of 2 fellows per year, totaling 6-fellows program. As Program Director of the HM Hematology- Oncology Fellowship Program, I had the oversight of curriculum and evaluation, fellows’ learning environment, supervision of residents and fellows, including duty hours, and program management (e.g., program evaluation and improvement, communications, ACGME accreditation, program resources), while functioning as faculty teachers, coaches, mentors, advisors and role models to the fellows. Because minimal administrative support, I also performed all the logistics and administrative aspects of the program, making sure that the program remained complaint with all the ACGME requirements. I was responsible for the mentoring of junior faculty on educational track and ensuring all key faculty-physicians meeting all the requirements of ACGME. The HM program had matched with the top 5 positions for 2 consecutive years since participating in the National Resident Matching Program (NRMP). I developed all curriculum and was responsible for all the clinical and didactic teaching for the HM Hematology-Oncology fellows, rotating internal medicine residents and interns of the HM Internal Medicine Residency Program, as well as medical students from the Houston- area medical schools (University of Texas, Texas A&M, and Baylor Medical College). I supervised and mentored national and international observerships. I am also the Chair of all the HM Hospital Cancer Education Committee, responsible functioning and compliance for hospital Tumor Registry, more than 11 multidisciplinary Tumor Boards, Oncology Grand Rounds, all aspects and programs relating to oncology CME and cancer outreached programs. |
INSTITUTIONAL / HOSPITAL / EMPLOYMENT RESPONSIBLITIES: |
07/2000 - 01/2013 University of Texas M D Anderson Cancer Center; I was trained at the University of Texas M D Anderson Cancer Center and joined Department of GI Medical Oncology as faculty in 2003. I was very productive in clinical practice, specialized my patient care and clinical research in GI malignancies particularly Neuroendocrine Tumors, Upper Gastrointestinal Cancers, and Rare Endocrine Malignancies. My time at MD Anderson was divided between clinical care, clinical research and education.
Total Efforts Percentage
Clinical Care 60%
Education 18%
Research 20%
Administrative/Programmatic/Leadership 2%
Total = 100%
|
01/2013 - 01/2015 Houston Methodist Cancer Center; In my position as Houston Methodist Cancer Center, I served as many positions including Medical Director of Clinical Research, and Medical Director of GI Medical Director. I founded a new ACGME accredited Hematology-Oncology Fellowship Program.
Total Efforts Percentage
Clinical Care 70%
Education 15%
Research 10%
Administrative/Programmatic/Leadership 5%
Total = 100%
|
01/2015 - 03/2015 Phan & Associates LLC; In May 2015, I had founded Phan & Associates LLC to service as a consultation services, both for clinical care, research, education and building programs. During this time, I served as founder, managing member. With the purpose of building brand through service excellence, marketing and strategic partnership and contracting. I worked on my company until I moved on to the next academic leadership position with University of New Mexico.
Total Efforts Percentage
Consultation/Education 80%
Administrative/Programmatic/Managing 20%
Total = 100%
|
03/2015 - 03/2016 University of New Mexico NCI Comprehensive Cancer Center; I came to University of New Mexico Cancer Center as Director of GI Working Group of the NCI designated Cancer Center with Endowed Professorship. I came in May of 2016 and started developing the program and recruit more GI medical oncologists. I was able to recruit Dr. Heloise Soares from Moffitt to lead Pancreatic Cancer Multidisciplinary Program. I had to leave for health and family reasons back to Houston and then to other opportunities.
Total Efforts Percentage
Clinical Care 70%
Research 15%
Administrative/Programmatic/Leadership 15%
Total = 100%
|
03/2017 - 08/2018 CTCA Southeastern Regional Medical Center; In my position as Medical Director of GI Medical Oncology at CTCA at Southeastern Regional Medical Center, as well as the Enterprise/National Director of the Gastrointestinal Institute within the Medicine & Science of CTCA 5 hospitals, I had the leadership role of establishing best-practice pathways, defining strategic clinical research program and clinical distinctiveness programs.
Total Efforts Percentage
Clinical Care 70%
Research 15%
Administrative/Programmatic/Leadership 15%
Total = 100%
|
08/2018 - 01/2019 Phan & Associates LLC, during this time, I resumed my consultative services in this firm that I have founded in May 2015. I had founded Phan & Associates LLC to service as a consultation services, both for clinical care, research, education and building programs. My role during this time was as managing member.
Total Efforts Percentage
Consultation/Education 80%
Administrative/Programmatic/Managing 20%
Total = 100%
|
01/2019 - 09/2021 University of Texas Health Science Center at Tyler I was recruited to be the Medical Director of the UTHSC Tyler-MD Anderson Cancer Center and to lead the expansion of the cancer service line as UT Tyler and Ardent merged into UT Health East Texas. This was system expansion of 10 hospitals and several private practice group. I had the leadership role of defining culture values, establishing best- practice pathways, defining strategic clinical research program and clinical distinctiveness programs for the UT Tyler-MD Anderson Cancer Center and UT Health East Texas cancer services.
During my tenure, I have led a successful acquisition of eight-physician hematology- oncology practice to gain the majority share of cancer services in the east Texas area. I also have led the consolidation and integration of 8 cancer conferences (or tumor boards), and two CoC accredited Cancer Center. I also developed several clinical programs that were of important value for the cancer service lines and providing unmet need to the community of rural east Texas. These clinical programs were part of my 3 pillars of program building strategy: innovation, research and education. I introduced and developed the novel Theranostic Clinical Program, including predictive imaging and targeted radioactive therapy, which potentially can generate two million annually to the system. I established a much-needed Cancer Genetic Clinical Program to the rural east Texas area. I had successfully collaborated with other institutions within the University of Texas, resulting in funding of 2 grants – NCI P30 and Texas CPRIT. During my tenure, I also integrated and expanded clinical research, with more than 50+ clinical trials.
Total Efforts Percentage
Clinical Care 40%
Research 20%
Administrative/Programmatic/Leadership 40%
Total = 100%
|
2021 - Present Phan & Associates LLC, since leaving Tyler, I resumed my private practice and consultative services in this firm that I have founded in May 2015. I had founded Phan & Associates LLC to service as a consultation services, both for clinical care, research, education and building programs. My role during this time was as managing member.
Total Efforts Percentage
Consultation/Education 80%
Administrative/Programmatic/Managing 20%
Total = 100%
|
INSTITUTIONAL / HOSPITAL AFFILIATIONS: |
2016 University of New Mexico Hospital (Albuquerque, NM); Primary |
2018 Houston Methodist Hospital, Willowbrook (Willowbrook, TX); Secondary |
2018 CHI St. Luke’s Hospital, Medical Center (Houston, TX); Secondary |
2018 Houston Methodist Hospital, West Houston (Katy, TX); Secondary |
2018 Houston Methodist Hospital, Medical Center (Houston, TX); Primary |
2018 Houston Methodist Hospital, Sugar Land Center (Sugar Land, TX); Secondary |
2019 CTCA – Southeastern Regional Medical Center (Atlanta, GA); Primary |
2021 University of Texas Health Science Center at Tyler (Tyler, TX); Primary |
RESEARCH DESCRIPTION OF RESPONSIBILITIES AND ACTIVITIES: |
07/2000 - 01/2013 University of Texas M D Anderson Cancer Center
Total Efforts Percentage Research 20%
Twenty percent of my time was dedicated to clinical and outcome research focusing on upper GI / endocrine malignancies and neuroendocrine tumors. During my tenure at MD Anderson, I had been involved as principal investigator (PI), co-PI, or collaborator in many phases I, II, III and even past approval observational phase IV studies. These studies / protocols were investigator initiated, cooperative and pharmaceutical clinical trials involving national and international collaboration. My efforts at MD Anderson in clinical research had resulted in 2 new FDA approved therapeutic agents in management of advanced neuroendocrine tumor, everolimus and lanreotide. |
01/2013 - 01/2015 Houston Methodist Cancer Center
Total Efforts Percentage Research 10%
Ten percent of my time was reserved for clinical research. I had utilized clinical research mechanisms within the cooperative groups (SWOG, NSABP, NCCN, and RTOG) as well as develop investigator initiated clinical studies to develop and open new protocols in GI and rare malignancies to Houston Methodist. Despite having seven other matured well-established general oncology practices within the HM Cancer Center, patients from my 3-years clinical practice contributed 100% accrual for protocols opened in GI and rare malignancies. I am collaborating with the HM Research Institute on several projects including targeted/novel imaging for neuroendocrine tumor, patient-derived xenografts for GI and neuroendocrine cancers, as well as end-of- life patient outcomes. |
03/2017 - 08/2018 CTCA Southeastern Regional Medical Center
Total Efforts Percentage Research 15%
My focus remained clinical research focusing on therapeutic trials ranging from Phase I-IV, both investigator- initiated and industry-sponsored. Because of my extensive clinical research experience at MDACC and my experience with expanding clinical research from one site to system wide, I was also involved with the enterprise initiative to formulate a centralized research hub the corporate office. This entails ensuring every regional medical center had consistently trained and staffed research personnel, while contract, regulation, and safety monitoring were being coordinated via central location. I was site Principal Investigator for all GI therapeutic protocols. Since clinical research was relatively new at this new hospital, my goals were to open more clinical trials to offer our patients. Over the course of 12 months, under my guidance we had opened 50% more GI cancer therapeutic protocols and improved accrual to clinical trials by 70%. |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Gukasyan J, Phan AT, Hu J, Zaher S, Arabian S, Hasan M, Vo D. Left-Sided Transudative Chylothorax With Concomitant Chylous Ascites in the Setting of Liver Cirrhosis. Cureus. 2023 Jan;15(1):e33866. PMCID: PMC9933419 |
Books, Chapters, and Reviews |
1. Phan AT, Ajani JA. Chapter 13-Combined Modality Therapy in Gastric, Pancreatic, and Biliary Tract Carcinomas. In: Chemoradiation in Cancer Therapy. Ed(s) Hak Choy. Humana Press,2003. |
2. Phan AT, Ajani JA. Gastric Cancer. In: Evidence-based oncology. BMJ Books,2003. |
3. Phan AT, Reddy S, Yao JC, Ajani JA. Carcinoma of the Esophagus and Gastric. In M D Anderson Manual of Clinical Oncology. Ed(s) Kantarjian H, Wolff RA, Koller C. McGraw-Hill,2005. |
4. Phan AT, Valero V. Carcinoma of the Esophagus and Gastric. In: MD Anderson Manual of Clinical. Ed(s) Kantarjian H, Wolff RA, Koller C. McGraw-Hill, 2005. |
5. Phan AT, Kavanaugh J. Carcinoma of the Esophagus and Gastric. In: MD Anderson Manual of Clinical. Ed(s) Kantarjian H, Wolff RA, Koller C. McGraw-Hill,2005. |
6. Phan AT, Hoff PM. Small cell carcinomas of the GI tract. In: Textbook of Uncommon Cancer. Ed(s) Meropol N. Wiley, 2005. |
7. Phan AT. Adrenal cortical carcinoma--review of current knowledge and treatment practices. Hematol Oncol Clin North Am. 2007 Jun;21(3):489-507;viii-ix. |
8. Phan AT. Gastroesophageal Carcinoma. In: M D Anderson Manual of Clinical Oncology. Ed(s) Kantarjian H, Wolff RA, Koller C. McGraw-Hill,2011. |
9. Phan AT and Jimenez C. Adrenocortical carcinoma. In: Neuroendocrine Tumors. Ed. Yao JC. Springer, 2011. |
10. Vikram R, Patnana M, Devine K, Mansfield P, Phan AT. Gastric Carcinoma. In: Oncologic Imaging. Ed. Silverman PM. Elsevier,2011. |
11. Garg R, Agrawal M, Quintas-Cardama A, Phan AT. Targeted Therapy for Endocrine Neoplasms.In: Targeted Therapy in the Age of Personalized Cancer Care. Ed(s): Qintas- Cardaman A, Cataldo V, Gibbons D. Nova Science. 2011. |
12. M Agrawal, Garg R. Quintas-Cardama A, Phan AT. Targeted Therapy for Gastrointestinal Carcinomas. In: Targeted Therapy in the Age of Personalized Cancer Care. Ed(s): Qintas- Cardaman A, Cataldo V, Gibbons D. Nova Science.2011. |
13. Phan AT, Mansfield P. Gastric Cancer. In: M D Anderson Cancer Center 100 years of History. Ed(s) Rodriguez A, Burke T. McGraw-Hill,2013. |
Editorials, Letters to Editor, Other |
1. Phan AT, Yao JC, Evans DB. Treatment options of metastatic neuroendocrine tumors – an editorial. Surgery. 2008Dec;144(6):895-8.
|
2. Yao JC and Phan AT. Anti-angiogenic therapy: Mechanism of resistance and potential strategies for the future. Clinical Cancer Res. Epub 2011; 17(16):1-3. |
Abstracts |
1. AT. Phan, EM. Wolin, N. Liyanage, B. Mirakhur, SW. Pitman Lowenthal, A. Vinik, GA. Fisher, and M Pavel. Effect of lanreotide depot (LAN) on 5-hydroxyindoleacetic acid (5HIAA) and chromogranin A (CgA) in gastroenteropancreatic neuroendocrine (GEP NET) tumors: Correlation with tumor response and progression-free survival (PFS) from the phase III CLARINET study. ASCO 2017, Abstr 4095. |
2. Hoff PM, Hoff AO, Phan AT, Sherman SI, Yao JC, White N, Phan L, Abbruzzese JL, Gagel RF. Phase I/II trial of capecitabine (C), dacarbazine (D) and imatinib (I) (CDI) for patients (pts) metastatic medullary thyroid carcinomas (MTC). ASCO 2006, abstract 13048. |
3. Phan AT, Wang L, Xie K, Zhang J, Rashid A, Evans D, Vauthey J, Abdalla E, Abbruzzese JL, Yao JC. Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma. ASCO 2006, abstract4091. |
4. Lenz H, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara H, Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with advanced gastric carcinoma in a multi-center phase II study. ASCO 2006, abstract 4083. |
5. Phan AT, Chang DZ, Rashid A, Meric-Bernstam F, Yao JC. Phase II study of RAD001 and Depot Octreotide in patients with advanced low. 8th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 6/2006. |
6. Phan AT, Evans DB, Lee JE, Rena V, Sellin J, Vauthey JN, Yao JC. Adrenocortical Carcinoma: Multidisciplinary Approach. 92nd Annual American College of Surgeons Clinical Congress ACS, 10/2006. |
7. Phan AT, Yao JC, Jacobs C, Mares JE, Meric-Bernstam F. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). ASCO 2006 Abstract#178 |
8. Ajani JA, Phan AT, Ho L, Tetzlaff ED, Baker J, Wei Q. Phase I/II trial of docetaxel plus oxaliplatin and 5- fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer. ASCO 2007, abstract 4612. |
9. Yao JC, Phan AT, Chang DZ, Wolff RA, Jacobs C, Mares JE, Gupta S, Meric-Bernstam F, RashidA. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low- grade neuroendocrine carcinoma (LGNET). ASCO 2007, abstract 4503. |
10. Mares JE, Eisner MP, Dagohoy C, Phan AT, Rashid A, Evans DB, Yao JC. Population based study of islet cell carcinoma. ASCO 2007, abstract15103. |
11. Phan AT, Takimoto C, Matsuno K, Fujisawa T, Adinin R, Wood L, Xiong H, Berram M. Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors. AACR- NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics, National Cancer Institute 2007. |
12. Mani MA, Shroff RT, Jacobs C, Wolff RA, Ajani JA, Yao JC, Phan AT. A phase II study of irinotecan and cisplatin for metastatic or unresectable high-grade neuroendocrine carcinoma. ASCO 2008, abstract 15550. |
13. Meric-Bernstam F, Rashid A, Crosby K, Phan AT, Chang DZ, Gupta S, Hernandez M, Akcakanat A, Yao JC. Biomarker Analysis for the Phase II study of RAD001 and Sandostatin in Advanced Log Grade Neuroendocrine Carcinoma. AACR 2008, abstract 2807. |
14. Qin A, Watermill J, Mastico RA, Lutz RJ, O’Keeffe J, Zildjian S, Mita AC, Phan AT, Tolcher AW. The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg- expressing solid tumors. ASCO 2008, abstract3066. |
15. Ho, L, Phan AT, Jhamb J, Mani M, Tetzlaff E, Lin E, Ajani JA, Abbruzzese JL, Overman MJ. Retrospective review of docetaxel, cisplatin, and 5FU (DCF) given on a weekly basis for the treatment of advanced gastric or esophageal cancer. ASCO 2008, abstract 15525. |
16. Tolcher A, Watermill J, Mastico RA, Lutz RJ, Keeffe J , Zildjian S, Phan A, Mita A, Qin A. A Novel Dosing Strategy Based on Plasma Levels of Canag in a Phase II Study of Imgn242 (Huc242-Dm4) in Gastric Cancer. 20th EORTC- NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics October 2008. |
17. Bose D., Badgwell B., Cormier J. N., Wen S, Yao J. C., Staerkel G. A., Crane C. H., Pisters P. W., Phan A., Mansfield
|
18. P. F. Association of neoadjuvant chemoradiation with improved survival in resectable gastric cancer. GI ASCO 2009, abstract76 |
19. Kazmi S. M., Jhamb J., Joseph M., Lin E., Abbruzzese J. L., Ajani J., Phan A., Overman M. J. Toxicity and efficacy of a weekly-based docetaxel, cisplatin, and 5FU (DCF) as first-line treatment for advanced gastric and esophageal cancer. GI ASCO 2009, abstract 68 |
20. Sun CC, Ramondetta LM, Jhingran A, Eifel PJ, Crane C, Phan AT, Frumovitz MM, Elting LS, Bodurka DC. Patient preferences for chemoradiation-related side effects. ASCO 2009, abstract e20604 |
21. Goff L. W., Papadopoulos K., Posey J. A., Phan A.T., Patnaik A., Miller J. G., Zildjian S., O'Leary J. J., Qin A., Tolcher A. A phase II study of IMGN242 (huC242-DM4) in patients with CanAg- positive gastric or gastroesophageal (GE) junction cancer. ASCO 2009, abstract e15625 |
22. Sankhala K. K., Mita A. C., Adinin R., Wood L., Beeram M., Bullock S., Yamagata N., Matsuno K., Fujisawa T., Phan A. A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. ASCO 2009, abstract2535 |
23. Shama MA, Kaseb AO, Vauthey J, Hassan M, Phan AT, Siddiqui AM, Nooka AK, Abbruzzese JL, Curley SA. Retrospective analyses of 52 patients with fibrolamellar hepatocellular carcinoma: Treatment outcome and prognostic indications. ASCO GI 2010. Abstr203 |
24. Cella D, Beaumont JL, Liu Z, Phan AT, Choi S, Yao JC. Neuroendocrine tumor disease state and PROMIS health- related quality of life scores. ASCO 2010. Abstr 6118 |
25. Bodurka DC, Jhingran A., Ramodetta LM, Eifel PJ, Crane CH, Phan AT, Urbauer D, FrumovitzMM, Elting LS, Sun CC. Visual analog scale (VAS) and time trade-off (TTO) preferences for side effects (SE) of chemoradiation (chemoXRT): A comparison of patients (pts) and caregivers (CG). ASCO 2010. Abstr 9056. |
26. Sun CC, Jhingran A, Ramodetta LM, Eifel PJ, Crane CH, Phan AT, Urbauer D, Frumovitz MM, Elting LS, Bodurka DC. Gynecologic versus gastrointestinal patients: Preferences (prefs) over time for chemoradiation (chemoXRT) side effects (SE) using visual analog scale (VAS) and time trade-off (TTO). ASCO 2010. Abstr e19616.
|
27. Beaumont JL, Liu Z, Choi S, Yao JC, Phan AT, Cella D. Relationship between neuroendocrine tumor- related symptoms and health-related quality of life. ASCO GI 2010. Abstr 242. |
28. Beaumont JL, Liu Z, Choi S, Yao JC, Phan AT, Cella D. Relationship between neuroendocrine tumor- related symptoms and PROMIS health-related quality-of-life scores. ASCO 2010. Abstr 6109. |
29. Yao JC, Phan AT, Fogleman D, Ng CS, Jacobs CB, Dagohoy CD, Leary C, Hess KR. Randomized run- in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. ASCO 2010. Oral Presentation. Abstr 4002. |
30. Dong, J.L. Beaumont, Z. Liu, A.T. Phan, S. Choi, D. Cella, J.C. Yao. Somatostatin analogue therapy and PROMIS health-related quality-of-life scores in patients with neuroendocrinetumors. ASCO 2010. Abstr 4110 |
31. Phan AT, Yao JC, Fogleman D, Hess KR, Ng CS, Bullock SA, Malinowski P, Regan E, Kulke M. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (Sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). ASCO 2010. Oral Presentation. Abstr 4001. |
32. Phan AT, Beaumont JL, Liu Z, Choi S, Cella D, Yao JC. Neuroendocrine tumor disease state and health-related quality of life. ASCO GI Symposium 2010. Abstr270. |
33. Ko AH, Tabernero J, Garcia De Paredes M, Rivera F, Schnell FM, Baker JS. Phan AT, Alsina M, Patel K, Ajani JA. Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction (GEJ). ASCO 2010. Abstre14575. |
34. Chen, G.P. Hess, Z. Liu, J.C. Yao, A.T. Phan, J.W. Hill. Risk of anxiety/depression events in patients newly diagnosed with neuroendocrine tumors. ASCO 2011. Abstr e16591 |
35. J.W. Hill, C. Chen, G.P. Hess, Z. Liu, J.C. Yao, A.T. Phan. Risk of osteoporosis/osteopenia events in patients newly diagnosed with neuroendocrine tumors. ASCO 2011. Abstr e16602 |
36. T. M. O'Dorisio, A.T. Phan, R.M. Langdon, B.J. Marek, N. Ikhlaque, E.K. Bergsland, J. Freiman, L. Law, P.L. Banks, K. Frazier, J. Jackson, B. Zambrowicz, M. Kulke. Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a double-blind, placebo- controlled multicenters study. ASCO GI Symposium 2012. Abstr 312 |
37. T. M. O'Dorisio, A.T. Phan, R.M. Langdon, B.J. Marek, N. Ikhlaque, E.K. Bergsland, J. Freiman, L. Law, P.L. Banks, K. Frazier, J. Jackson, B. Zambrowicz, M. Kulke. Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a double-blind, placebo- controlled multicenters study. ASCO 2012. Abstr 4085 |
38. S. Yennurajalingam, S. Frisbee-Hume, M.O. Delgado-Guay, J. Bull, A.T. Phan, N.M. Tannir, J.K. Litton, J.L. Palmer, A.S. Reddy, D. Hui, S. Dalal, L. Massie, S. Vadhan-Raj, S.K. Reddy, J.M. Reuben, E. Bruera. Dexamethasone (DM) for cancer-related fatigue: A double-blinded, |
39. M.A. Habra, S. Ejaz, L. Feng, P. Das, F. Deniz, E.G. Grubbs, A.T. Phan, S. Waguespack, M. Ayala- Ramirez, C. Jimenez, R. Vassilopoulou-Sellin. Adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma: Retrospective cohort analysis. ASCO 2012. Abstr 4641 |
40. A.T. Phan, E.M. Wolin, J.A. Chan, J.M. Huang, M. Hudson, G. Hughes, G. Shen, J.R. Strosberg. Phase I dose- escalation study of pasireotide LAR in patients with advanced neuroendocrine tumors. ASCO 2013. Abstr e15126 |
41. M.E. Caplin, P.B. Ruszniewski, M.E. Pavel, J.B. Cwikla, A.T. Phan, M. Raderer, E. Sedlackova, G. Cadiot, L.R. Wall, G. Rindi, A. Langley, J. Blumberg, CLARINET Study Group. Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study. ASCO 2014. Abstr 4107 |
42. A.T. Phan, M.E. Caplin, M.E. Pavel, J.B. Cwikla, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, E. Gomez-Panzani, P.B. Ruszniewski, on behalf of the CLARINET Study Group. Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs). ASCO 2015. Abstr e15181
|
43. E.M. Wolin, M.E. Caplin, M.E. Pavel, J.B. Cwikla, A.T. Phan, M. Raderer, E. Sedlackova, G. Cadiot, J. Capdevila, L. Wall, G. Rindi, A.Langley, E. Gomez-Panzani, P.B. Ruszniewski, CLARINET Study Group. Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs). ASCO 2015. Abstr e15180 |
44. A.M. Manon, E.M. Wolin, C. Chassaing, A.L. Lewis, L. Bertocchi, J. Richard, A.T. Phan. Pharmacokinetic differences between subcutaneous and intramuscular administration of lanreotide: Results from a phase I study. ASCO 2015. Abstr e15186 |
45. A.D. Dasari, A.T. Phan, M.E. Caplin, M.E. Pavel, J.B. Cwikla, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, E. Gomez-Panzani, P.B. Ruszniewski, on behalf of the CLARINET Study Group. Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study. ASCO 2015. Abstr e15177 |
46. A.T. Phan, M.E. Caplin, M.E. Pavel, J.B. Cwikla, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, E. Gomez-Panzani, P.B. Ruszniewski, on behalf of the CLARINET Study Group. Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study. ASCO 2015. Abstr e15178
|
47. A.D. Dasari, A.T. Phan, M.E. Caplin, M.E. Pavel, J.B. Cwikla, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, E. Gomez-Panzani, P.B. Ruszniewski, on behalf of the CLARINET Study Group. Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study. ASCO 2015. Abstr 4104 |
48. E.M. Wolin, M.E. Caplin, M.E. Pavel, J.B. Cwikla, A.T. Phan, M. Raderer, E. Sedláčková, G. Cadiot, J. Capdevila, L. Wall, G. Rindi, A. Langley, E. Gomez-Panzani, P.B. Ruszniewski, on behalf of the CLARINET Study Group. Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study. ASCO 2015. Abstr e15182 |
49. A.T. Phan, M.E. Caplin, M.E. Pavel, J.B. Cwikla, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, E. Gomez-Panzani, P.B. Ruszniewski, on behalf of the CLARINET Study Group. Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study. ASCO GI Symposium 2015. Abstr 367 |
50. A.T. Phan, M.E. Caplin, M.E. Pavel, J.B. Cwikla, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, E. Gomez-Panzani, P.B. Ruszniewski, on behalf of the CLARINET Study Group. Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study. ASCO GI Symposium 2015. Abstr 233 |
51. P.S. Teegavarapu, B. Dave, A.T. Phan. Scientific rationale for revisiting targeting mTOR pathway in gastric cancer. ASCO 2016. Abstr e15558 |
52. A.T. Phan, A. Dasari, N. Liyanage, D. Cox, S. Pitman Lowenthal, E.M. Wolin. Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ASCO 2016. Abstr 434. |
53. EM. Wolin, M. Pavel, JB. Cwikla, AT. Phan, M. Raderer, E. Sedlackova, G. Cadiot, J. Capdevila, L. Wall, G. Rindi, C. Lombard-Bohas, N. Liyanage, XM. Truong Thanh, P. Ruszniewski, and ME. Caplin, CLARINET Investigators. Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study. ASCO 2017, Abstr 4089.
|
54. AT. Phan, EM. Wolin, GA. Fisher, PB. Ruszniewski, ME. Pavel, N. Liyanage, K. Strutt, S. Braun, ME. Caplin, and A. Vinik. Safety and tolerability of lanreotide autogel/depot (LAN) in patients (pts) with neuroendocrine tumors (NETs): Pooled analysis of clinical studies. ASCO GI Symposium 2017, Abstr 398. |
55. Iyer, Renuka V., Daneng Li, Farshid Dayyani, Alexandria T. Phan, Michael N. Needle, and Thomas Adam Abrams. "DEDUCTIVE: A study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma—Phase Ib results." (2021): 294- 294. |
Peer Reviewed Educational Products |
1. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001 Jul 15;92(2):406-13. |
2. Kasakura Y, Phan A, Ajani J. Adjuvant therapy for resected gastric carcinoma. Surg Oncol Clin N Am. 2002 Apr;11(2):431-44, xii-xiii. |
3. Sarris AH, Phan A, Duvic M, Romaguera J, McLaughlin P, Mesina O, King K, Medeiros LJ, Rassidakis GZ, Samuels B, Cabanillas F. Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol. 2002 Jun 15;20(12):2876-80. |
4. Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, Bleyer AW, Cabanillas F. Irinotecan in relapsed or refractory non- Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park). 2002 Aug; 16(8 Suppl 7):27-31. |
5. Higuchi K, Phan AT, Ajani JA. Gastric Cancer: Advances in adjuvant and adjunct therapy. Curr Treat Options Oncology. 2003 Oct;4(5):413-419. |
6. Phan A, Patel S. Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol. 2003 Dec;4(6):433-439. |
7. Phan AT, Ajani JA. Gastric carcinoma. Curr Oncol Rep. 2004 May;6(3):192-8. |
8. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophagealcancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May;241(5):810-7; discussion817- 20. |
9. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography- identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72. |
10. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB 3rd, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Feb 01;24(4):663-7. |
11. Wang S, LiaoZ, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani J, Phan A, Swisher S, Allen P, Cox JD, Komaki R. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single- institution experience. J Thorac Oncol. 2006 Mar;1(3):252-9. |
12. Lenz HJ, Lee Fc, Haller DG, Singh D, Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan1;109(1):33-40. |
13. Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, Zhang L, Phan A, Fukami N, Luthra R. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007 Feb 1;13(3):912-9.
|
14. Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed Modification of Nodal Status in AJCC Esophageal Cancer Staging System. Ann Thorac Surg. 2007 Aug;84(2):365-73; discussion 374-5. |
15. Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans DB. Population- based study of islet cell carcinoma. Ann Surg Oncol. 2007 Dec;14(12):3492-500. Epub 2007 Sep26. |
16. Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery. 2007 Dec;142(6):867-75; discussion 867-75. |
17. Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008;47(3):421-7. |
18. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu C, Ajani JA, Phan A, Swisher SG, Mohan R, Cox JD, Komaki R. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thoracic Oncology. 2008 Mar;3(3):277-82. |
19. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL,Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10;26(8):1316- 23. |
20. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):959-65. |
21. Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys. 2008 May 01;71(1):167-72. |
22. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares, JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One Hundred Years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology.2008 Jun 20;26(18):3063-3072. |
23. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer. 2008 Aug 15;123(4):867- 73. |
24. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008 Sep 10;26(26):4311-8. PMCID: PMC2653122 |
25. Phan AT, Yao JC. Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology (Williston Park). 2008 Dec;22(14):1617-23; discussion 1623-4, 1629. |
26. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and other von Hippel-Lindau Disease-related Tumors. J Clin Endocrinol Metab. 2009 Feb;94(2):386-91. |
27. Phan AT, Oberg K, Choi J, Harrison LH Jr, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ, North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010 Aug;39(6):784-98. |
28. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, Lee JE. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010 Jan;17(1):263-70. |
29. Overman, MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15;116(6):1446-53. |
30. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01;116(7):1656-63. |
31. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010 Aug;39(6):799-800. |
32. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011 Mar;96(3):717-25. doi: 10.1210/jc.2010-1946. Epub 2010 Dec 29. |
33. Yao JC, Phan AT. Overcoming antiangiogenic resistance. Clin Cancer Res. 2011 Aug 15;17(16):5217-9. doi: 10.1158/1078-0432.CCR-11-1219. Epub 2011 Aug9. |
34. Jimenez P, Pathak A, Phan AT. The role of taxanes in the management of gastroesphageal cancer. J Gastrointest Oncol. 2011 Dec;2(4):240-9. PMCID: PMC3397631 |
35. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Öberg KE. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011 Dec;96(12):3741-9. |
36. Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012 Apr;41(3):461-6. |
37. Dong M, Phan AT, Yao JC. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res. 2012 Apr 01;18(7):1830-6. |
38. Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single- institutional experience. Cancer. 2012 Jun 1;118(11):2804-12. doi: 10.1002/cncr.26577. Epub 2011 Oct 17. |
39. Hess GP, Chen CC, Liu Z, Yao JC, Phan AT, Hill JW. Clinical burden of illness in patients with neuroendocrine tumors. Pancreas. 2012 Oct;41(7):1058-62. |
40. Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan A, Waguespack SG, Ayala- Ramirez M, Jimenez C, Perrier ND, Lee JE, Vassilopoulou-Sellin R. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013 Jan;98(1):192-7. |
41. Phan AT. Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective. Cancer Treat Rev. 2013 Feb;39(1):3-9. |
42. Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res. 2013 Mar 01;73(5):1449-53. |
43. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 05;108(4):826-30. PMCID: PMC3590681 |
44. Weissferdt A, Phan A, Suster S, Moran CA. Primary rhabdoid adrenocortical carcinoma: a clinicopathological and immunohistochemical study of three cases. Histopathology. 2013 Apr;62(5):771-7. |
45. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC, North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-77. PMCID: PMC4304762 |
46. Weissferdt A, Phan A, Suster S, Moran CA. Myxoid adrenocortical carcinoma: a clinicopathologic and immunohistochemical study of 7 cases, including 1 case with lipomatous metaplasia. Am J Clin Pathol. 2013 Jun;139(6):780-6. |
47. Landry CS, Lin HY, Phan A, Charnsangavej C, Abdalla EK, Aloia T, Nicolas Vauthey J, Katz MH,Yao JC, Fleming JB. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013 Jul;37(7):1695-700. |
48. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013 Sep 01;31(25):3076-82. |
49. Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan A, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. 2013 Nov;24(11):2844-9. |
50. Weissferdt A, Phan A, Suster S, Moran CA. Adrenocortical carcinoma: a comprehensive immunohistochemical study of 40 cases. Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):24- 30. |
51. Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N, Evans DB, Katz MH, Ng CS, Perrier ND, Lee JE, Grubbs EG. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. World J Surg. 2014 Jun;38(6):1318-27. |
52. Kong R, Liu T, Zhu X, Ahmad S, Williams AL, Phan AT, Zhao H, Scott JE, Yeh LA, Wong ST. Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. Clin Cancer Res. 2014 Jul 01;20(13):3521-30. PMCID: PMC4079752 |
53. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. |
54. Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer. 2014 Aug 02;14:561. PMCID: PMC4125701 |
55. Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct;21(5):705-14. |
56. Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL Jr, Macapinlac HA, Chuang HH. Impact of ¹⁸F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2066-73. |
57. Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 2015 Mar;44(2):190-7. PMCID: PMC6063309 |
58. Phan AT. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clin Adv Hematol Oncol. 2014 Dec;12(12 Suppl 19):3-5. |
59. Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. 2015 Jul;149(1):119-29. PMCID: PMC4778392 |
60. Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2015 Jun;22(3):431- 41. |
61. Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun;16(6):695-703. PMCID: PMC4800487 |
62. Phan AT. Lanreotide depot/autogel in neuroendocrine tumors: subgroup analyses from the CLARINET study. Clin Adv Hematol Oncol. 2015 Aug;13(8 Suppl 8):6-8. |
63. Boston CH, Phan A, Munsell MF, Herzog CE, Huh WW. A Comparison Between Appendiceal and Nonappendiceal Neuroendocrine Tumors in Children and Young Adults: A Single-Institution Experience. J Pediatr Hematol Oncol. 2015 May 12. |
64. Crumley SM, Pepper KL, Phan AT, Olsen RJ, Schwartz MR, Portier BP. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas. Arch Pathol Lab Med. 2016 Jun;140(6):529-35. |
65. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P; CLARINET Investigators. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016 Mar;23(3):191- 9. |
66. Blum Murphy MA, Qiao W, Mewada N, Wadhwa R, Elimova E, Takashi T, Ho L, Phan A, Baker J, Ajani J. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients with Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol. 2016 Feb 22. |
67. Phan AT, Dave B. The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. Cancer Med. 2016 Oct;5(10):2953- 2964. |
68. Ryan P, Phan AT, Adelman DT, Iwasaki M. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences. Clin J Oncol Nurs. 2016 Dec 1;20(6): E139-E146. |
69. Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J, Phan AT. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. J Gastrointest Cancer. 2016 Dec;47(4):366- 374. |
70. Ryan P, Phan AT, Adelman DT, Iwasaki M. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences. Clin J Oncol Nurs. 2016 Dec 1;20(6): E139-E146. |
71. Nan X, Qin Q, Gentille C, Ensor J, Leveque C, Pingali SR, Phan AT, Rice L, Iyer S. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center. Leuk Lymphoma. 2017 Jan 31:1-11. |
72. Iyer R, Phan AT, Boudreaux JP. Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: Insights from the 2017 ASCO Gastrointestinal Cancers Symposium. Clin Adv Hematol Oncol. 2017 Apr;15 Suppl 4(4):1-24. |
73. Phan AT. Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors. Clin Adv Hematol Oncol. 2017 Apr;15 Suppl 4(4):10-14. |
74. Iyer R, Phan AT, Boudreaux JP. Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: Discussion. Clin Adv Hematol Oncol. 2017 Apr;15 Suppl 4(4):18-19. |
75. Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res. 2017 Aug 16;9: 495- 503. doi: 10.2147/CEOR.S140866. eCollection 2017. |
76. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women with Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1791-1799. doi: 10.1016/j.cgh.2017.05.036. Epub 2017 Jun 1. |
77. Yu Y, Kong R, Cao H, Yin Z, Liu J, Nan X, Phan AT, Ding T, Zhao H, Wong STC. Two birds, one stone: hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition. Oncotarget. 2018 Feb 23;9(46):27958-27973. doi:10.18632/oncotarget.24563. eCollection 2018 Jun 15. |
78. Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, Lowenthal SP, Vinik AI. Biochemical Responses in Symptomatic and Asymptomatic Patients with Neuroendocrine Tumors: Pooled Analysis of 2 Phase 3 Trials. Endocr Pract. 2018 Aug 7. doi: 10.4158/EP-2018-0296. [Epub ahead of print] |
79. Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators. Effect of Lanreotide Depot/Autogel on Urinary 5- Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist. 2018 Oct 24. pii: theoncologist.2018- 0217. doi: 10.1634/theoncologist.2018-0217. [Epub ahead of print] |
80. Khalife M, Shahid K, Dabney R, and Phan AT. Stereotactic Body Radiation Therapy and Immunotherapy. Clin Adv Hematol Oncol. 2019 Sep;17(9):518-523. |
81. Shahid K, Khalife M, Dabney R, and Phan AT. Immunotherapy and Targeted Therapy-The New Roadmap in Cancer Treatment. Ann Transl Med. 2019 Oct;7(20):595. |
82. Klink AJ, Feinberg B, Yu HT, Ray D, Pulgar S, Phan A, and Vinik A. Patterns of Care Among Real- World Patients with Metastatic Neuroendocrine Tumors. Oncologist. 2019 Oct;24(10):1331- 1339. |
83. Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators. Effect of Lanreotide Depot/Autogel on Urinary 5- Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist. 2019 Apr;24(4):463-474. |
84. Dabney RS, Khalife M, Shahid K, Phan AT. Molecular pathways and targeted therapy in cholangiocarcinoma. Clin Adv Hematol Oncol. 2019 Nov;17(11):630-637. |
85. Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM. Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. Int J Cancer. 2020 Apr 1;146(7):1836-1840. Epub 2019 Jul 5. |
86. Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Truong Thanh XM, Caplin ME; CLARINET Study Group. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. Anticancer Drugs. 2020 Mar;31(3):216-222. |
87. Caplin, Martyn E., Marianne Pavel, Alexandria T. Phan, Jarosław B. Ćwikła, Eva Sedláčková, Xuan-Mai Truong Thanh, Edward M. Wolin, and Philippe Ruszniewski. "Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study." Endocrine 71, no. 2 (2021): 502-513. |
88. Zimmerman, Nicole M., David Ray, Nicole Princic, Meghan Moynihan, Callisia Clarke, and Alexandria Phan. "Exploration of machine learning techniques to examine the journey to neuroendocrine tumor diagnosis with real-world data." Future Oncology 0 (2021). |
Database, Video, or Other Research/Clinical Contributions |
1. Phan AT, Oberg K, Choi J, Harrison LH Jr, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ. The NANETS consensus guidelines for management of neuroendocrine carcinoma. Pancreas. 2010 Aug; 39(6)784-98. |
2. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high- grade)extra pulmonary neuroendocrine carcinoma. Pancreas. 2010; 39(6): 799-800. |
3. Phan AT, et all. American Joint Committee on Cancer. Cancer Staging version 8 on Adrenal Cortical Carcinoma. 2018 |
4. Phan AT, Yao J. The University of MD Anderson Cancer Center Color Matrix Approach - Gastric / Esophageal Cancer Section. 2000-2007.
|
5. Phan AT. The University of MD Anderson Cancer Center GI Medical Oncology Teaching Curriculums. 2003 - 2010 |
6. Phan AT. American Society of Clinical Oncology, Maintenance Certification Course, Geriatric Oncology Module. 2010-2011 |
